Streetbeat News

Stock Prices

AMZN

Amazon.com, Inc (NASDAQ:AMZN) is involved in a significant real estate transaction with the sale of two office buildings in downtown Vancouver for C$300 million ($223 million) to Germany's Deka Group. The sale price, lower than the expected C$350 million, reflects the challenges in the office real estate market due to high-interest rates and the trend towards remote work. This transaction is seen as an indicator of the commercial real estate sector's direction amidst economic shifts. Amazon's recent activities, including selling unutilized office spaces and suspending new constructions, alongside layoffs, suggest a strategic adjustment to market conditions.

Portfolio Pulse from Anusuya Lahiri

February 05, 2024 | 3:44 pm

BRTX

BioRestorative Therapies, Inc. (NASDAQ:BRTX) shares rose after presenting positive preliminary clinical data from a Phase 2 trial of BRTX-100 for chronic lumbar disc disease at the Orthopaedic Research Society 2024 Annual Meeting. The data showed a positive trend and no notable safety issues.

Portfolio Pulse from Erica Kollmann

February 05, 2024 | 3:42 pm

AAPL

NVDA

SSNLF

Samsung Electronics Co, led by Jay Y. Lee, was acquitted of stock manipulation charges, a significant legal victory allowing Lee to continue leading the company. This ruling comes as Samsung faces competition from Apple Inc in smartphones and SK Hynix Inc in AI, with plans to commercialize advanced chips by 2025 and 2027. The acquittal removes the threat of imprisonment for Lee, enabling him to focus on Samsung's challenges, including a downturn in the smartphone and memory chip markets. Nvidia Corp, a rival in the chip sector, saw its shares rise by 3.08% in premarket trading.

Portfolio Pulse from Anusuya Lahiri

February 05, 2024 | 3:41 pm

PLRX

Pliant Therapeutics' stock price is trading lower following HC Wainwright's decision to maintain a Buy rating but reduce its price target from $52 to $48.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:39 pm

MCD

McDonald's reported mixed Q4 financial results, leading to a decrease in its stock price.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:37 pm

REGN

RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and increased the price target from $1076 to $1110.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:35 pm

EL

EVBG

FDMT

ON

Estée Lauder reported better-than-expected Q2 results and announced a restructuring program, leading to a 14% stock increase. Other stocks like 4D Molecular Therapeutics, Everbridge, and ON Semiconductor also saw significant gains due to positive news such as clinical trial data, acquisitions, and strong financial results.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 3:32 pm

CNA

CNA Financial shares are trading higher following the announcement of their Q4 results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:31 pm

ANET

Arista Networks (NYSE:ANET) has seen a significant surge in options activity, with an unusual split of 50% bullish and 50% bearish sentiment among big-money traders. The options scanner revealed 16 uncommon trades, with a focus on a price band between $220.0 and $300.0. The largest trades include both puts and calls, with varying sentiments and strike prices. Arista Networks, a provider of networking equipment, has its stock price slightly up by 0.93% at $275.64, with an earnings announcement expected in 7 days. Market experts have issued positive ratings, with a consensus target price of approximately $297.67.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 3:31 pm

AVGO

Deep-pocketed investors are showing a bearish sentiment towards Broadcom (NASDAQ:AVGO), with a significant move detected by Benzinga's options scanner. The scanner revealed 38 unusual options activities, with a bearish majority of 63%. The focus is on a price band between $660.0 and $1480.0. Despite this, the current market status shows AVGO's price slightly down by -0.19% at $1222.0, with potential overbought signals. Analysts have recently downgraded their ratings but still maintain a target price around $1308.33.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 3:31 pm